Last $14.10 USD
Change Today +0.17 / 1.22%
Volume 545.3K
FLML On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 4:30 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

flamel technologies-sp adr (FLML) Snapshot

Open
$14.07
Previous Close
$13.93
Day High
$14.69
Day Low
$13.77
52 Week High
08/21/14 - $15.96
52 Week Low
11/25/13 - $6.90
Market Cap
544.0M
Average Volume 10 Days
224.1K
EPS TTM
$-0.83
Shares Outstanding
38.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLAMEL TECHNOLOGIES-SP ADR (FLML)

Related News

No related news articles were found.

flamel technologies-sp adr (FLML) Related Businessweek News

No Related Businessweek News Found

flamel technologies-sp adr (FLML) Details

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology. The company owns and develops drug delivery platforms, such as Micropump that allows generating and marketing modified and/or controlled release of solid and oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. Its drug delivery platforms also comprise Trigger Lock that develops tamper-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. The company’s lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Coreg CR, a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors used for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. It has collaborations with various pharmaceutical and biotechnology companies, including GlaxoSmithKline plc. Flamel Technologies SA was founded in 1990 and is headquartered in Vénissieux, France.

Founded in 1990

flamel technologies-sp adr (FLML) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

flamel technologies-sp adr (FLML) Key Developments

Flamel Technologies SA Reports Unaudited Consolidated Cash Flow Results for the Nine Months Ended September 30, 2014

Flamel Technologies SA reported unaudited consolidated cash flow results for the nine months ended September 30, 2014. For the period, the company reported net cash used in operating activities of $4,306,000 against $13,658,000 a year ago. Purchases of property and equipment were $1,404,000 against $766,000 a year ago.

Flamel Technologies SA Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Flamel Technologies SA reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. The company reported total revenues during the third quarter of 2014 of $7.0 million, an increase of $1.4 million in revenues compared to the prior year period. Net loss for the third quarter of 2014 was $10.0 million versus net loss of $6.4 million in the year-ago period. Loss per share (both basic and diluted) was $0.26 in the third quarter of 2014 versus $0.25 in the third quarter of 2013. Adjusted net loss (non-GAAP) for the third quarter of 2014 was $6.0 million versus $5.4 million in the third quarter of 2013. Adjusted loss per share (both basic and diluted) was $0.16 in the third quarter of 2014 versus $0.21 in the prior year period. For the quarter, the company reported loss from operations was $16,820,000 against $6,801,000 a year ago. Loss before income taxes was $10,075,000 against $7,597,000 a year ago. For the nine months, the company reported total revenue of $24,285,000 against $16,264,000 a year ago. Loss from operations was $60,958,000 against $51,027,000 a year ago. Loss before income taxes was $60,310,000 against $54,450,000 a year ago. Net loss was $57,757,000 or $1.64 per basic and diluted share against $48,052,000 or $1.89 per basic and diluted share a year ago. Adjusted net loss was $15,599,000 against $0.44 diluted per share against $15,847,000 against $0.62 diluted per share a year ago.

Flamel Technologies SA Presents at Barclays Select Series 2014: SMID Cap Conference, Nov-12-2014

Flamel Technologies SA Presents at Barclays Select Series 2014: SMID Cap Conference, Nov-12-2014 . Venue: Barclays headquarters, 745 Seventh Avenue, New York, NY 10019, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLML:US $14.10 USD +0.17

FLML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $14.95 USD +0.16
Onxeo €5.97 EUR +0.34
Skyepharma PLC 337.00 GBp +2.75
Veloxis Pharmaceuticals A/S kr1.00 DKK -0.01
XenoPort Inc $8.60 USD +0.19
View Industry Companies
 

Industry Analysis

FLML

Industry Average

Valuation FLML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.7x
Price/Book 13.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLAMEL TECHNOLOGIES-SP ADR, please visit www.flamel-technologies.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.